Ji Lu1, Peter E Lonergan2, Lucas P Nacusi2, Liguo Wang3, Lucy J Schmidt2, Zhifu Sun3, Travis Van der Steen2, Stephen A Boorjian2, Farhad Kosari4, George Vasmatzis4, George G Klee4, Steven P Balk5, Haojie Huang6, Chunxi Wang7, Donald J Tindall8. 1. Department of Urology, First Hospital of Jilin University, Changchun, People's Republic of China; Department of Urology, Mayo Clinic, Rochester, Minnesota. 2. Department of Urology, Mayo Clinic, Rochester, Minnesota. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 5. Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. 6. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota. 7. Department of Urology, First Hospital of Jilin University, Changchun, People's Republic of China. Electronic address: chunxi_wang@126.com. 8. Department of Urology, Mayo Clinic, Rochester, Minnesota; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota. Electronic address: tindall@mayo.edu.
Abstract
PURPOSE: Spliced variant forms of androgen receptor were recently identified in castration resistant prostate cancer cell lines and clinical samples. We identified the cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cell lines and determined the clinical significance of androgen receptor splice variant regulated genes. MATERIALS AND METHODS: The castration resistant prostate cancer cell line 22Rv1, which expresses full-length androgen receptor and androgen receptor splice variants endogenously, was used as the research model. We established 22Rv1-ARFL(-)/ARV(+) and 22Rv1-ARFL(-)/ARV(-) through RNA interference. Chromatin immunoprecipitation coupled with next generation sequencing and microarray techniques were used to identify the cistrome and gene expression profiles of androgen receptor splice variants in the absence of androgen. RESULTS: Androgen receptor splice variant binding sites were identified in 22Rv1-ARFL(-)/ARV(+). A gene set was regulated uniquely by androgen receptor splice variants but not by full-length androgen receptor in the absence of androgen. Integrated analysis revealed that some genes were directly modulated by androgen receptor splice variants. Unsupervised clustering analysis showed that the androgen receptor splice variant gene signature differentiated benign from malignant prostate tissue as well as localized prostate cancer from metastatic castration resistant prostate cancer specimens. Some genes that were modulated uniquely by androgen receptor splice variants also correlated with histological grade and biochemical failure. CONCLUSIONS: Androgen receptor splice variants can bind to DNA independent of full-length androgen receptor in the absence of androgen and modulate a unique set of genes that is not regulated by full-length androgen receptor. The androgen receptor splice variant gene signature correlates with disease progression. It distinguishes primary cancer from castration resistant prostate cancer specimens and benign from malignant prostate specimens.
PURPOSE: Spliced variant forms of androgen receptor were recently identified in castration resistant prostate cancer cell lines and clinical samples. We identified the cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cell lines and determined the clinical significance of androgen receptor splice variant regulated genes. MATERIALS AND METHODS: The castration resistant prostate cancer cell line 22Rv1, which expresses full-length androgen receptor and androgen receptor splice variants endogenously, was used as the research model. We established 22Rv1-ARFL(-)/ARV(+) and 22Rv1-ARFL(-)/ARV(-) through RNA interference. Chromatin immunoprecipitation coupled with next generation sequencing and microarray techniques were used to identify the cistrome and gene expression profiles of androgen receptor splice variants in the absence of androgen. RESULTS:Androgen receptor splice variant binding sites were identified in 22Rv1-ARFL(-)/ARV(+). A gene set was regulated uniquely by androgen receptor splice variants but not by full-length androgen receptor in the absence of androgen. Integrated analysis revealed that some genes were directly modulated by androgen receptor splice variants. Unsupervised clustering analysis showed that the androgen receptor splice variant gene signature differentiated benign from malignant prostate tissue as well as localized prostate cancer from metastatic castration resistant prostate cancer specimens. Some genes that were modulated uniquely by androgen receptor splice variants also correlated with histological grade and biochemical failure. CONCLUSIONS:Androgen receptor splice variants can bind to DNA independent of full-length androgen receptor in the absence of androgen and modulate a unique set of genes that is not regulated by full-length androgen receptor. The androgen receptor splice variant gene signature correlates with disease progression. It distinguishes primary cancer from castration resistant prostate cancer specimens and benign from malignant prostate specimens.
Authors: Qianben Wang; Wei Li; X Shirley Liu; Jason S Carroll; Olli A Jänne; Erika Krasnickas Keeton; Arul M Chinnaiyan; Kenneth J Pienta; Myles Brown Journal: Mol Cell Date: 2007-08-03 Impact factor: 17.970
Authors: Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown Journal: Cell Date: 2009-07-23 Impact factor: 41.582
Authors: Scott M Dehm; Lucy J Schmidt; Hannelore V Heemers; Robert L Vessella; Donald J Tindall Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Rong Hu; Thomas A Dunn; Shuanzeng Wei; Sumit Isharwal; Robert W Veltri; Elizabeth Humphreys; Misop Han; Alan W Partin; Robert L Vessella; William B Isaacs; G Steven Bova; Jun Luo Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701
Authors: Zhiyong Guo; Xi Yang; Feng Sun; Richeng Jiang; Douglas E Linn; Hege Chen; Hegang Chen; Xiangtian Kong; Jonathan Melamed; Clifford G Tepper; Hsing-Jien Kung; Angela M H Brodie; Joanne Edwards; Yun Qiu Journal: Cancer Res Date: 2009-02-24 Impact factor: 12.701
Authors: Dagmar M Kube; Cemile D Savci-Heijink; Anne-Françoise Lamblin; Farhad Kosari; George Vasmatzis; John C Cheville; Donald P Connelly; George G Klee Journal: BMC Mol Biol Date: 2007-03-21 Impact factor: 2.946
Authors: Yong Zhang; Tao Liu; Clifford A Meyer; Jérôme Eeckhoute; David S Johnson; Bradley E Bernstein; Chad Nusbaum; Richard M Myers; Myles Brown; Wei Li; X Shirley Liu Journal: Genome Biol Date: 2008-09-17 Impact factor: 13.583
Authors: Bo Cao; Yanfeng Qi; Guanyi Zhang; Duo Xu; Yang Zhan; Xavier Alvarez; Zhiyong Guo; Xueqi Fu; Stephen R Plymate; Oliver Sartor; Haitao Zhang; Yan Dong Journal: Oncotarget Date: 2014-03-30
Authors: Zhong Chen; Dayong Wu; Jennifer M Thomas-Ahner; Changxue Lu; Pei Zhao; Qingfu Zhang; Connor Geraghty; Pearlly S Yan; William Hankey; Benjamin Sunkel; Xiaolong Cheng; Emmanuel S Antonarakis; Qi-En Wang; Zhihua Liu; Tim H-M Huang; Victor X Jin; Steven K Clinton; Jun Luo; Jiaoti Huang; Qianben Wang Journal: Proc Natl Acad Sci U S A Date: 2018-05-29 Impact factor: 11.205
Authors: William C Reinhold; Sudhir Varma; Margot Sunshine; Fathi Elloumi; Kwabena Ofori-Atta; Sunmin Lee; Jane B Trepel; Paul S Meltzer; James H Doroshow; Yves Pommier Journal: Cancer Res Date: 2019-05-21 Impact factor: 12.701
Authors: Laura Cato; Jonas de Tribolet-Hardy; Irene Lee; Jaice T Rottenberg; Ilsa Coleman; Diana Melchers; René Houtman; Tengfei Xiao; Wei Li; Takuma Uo; Shihua Sun; Nane C Kuznik; Bettina Göppert; Fatma Ozgun; Martin E van Royen; Adriaan B Houtsmuller; Raga Vadhi; Prakash K Rao; Lewyn Li; Steven P Balk; Robert B Den; Bruce J Trock; R Jeffrey Karnes; Robert B Jenkins; Eric A Klein; Elai Davicioni; Friederike J Gruhl; Henry W Long; X Shirley Liu; Andrew C B Cato; Nathan A Lack; Peter S Nelson; Stephen R Plymate; Anna C Groner; Myles Brown Journal: Cancer Cell Date: 2019-02-14 Impact factor: 31.743
Authors: Fiorella Magani; Stephanie O Peacock; Meghan A Rice; Maria J Martinez; Ann M Greene; Pablo S Magani; Rolando Lyles; Jonathan R Weitz; Kerry L Burnstein Journal: Mol Cancer Res Date: 2017-08-15 Impact factor: 5.852
Authors: Ling Cai; Yi-Hsuan Tsai; Ping Wang; Jun Wang; Dongxu Li; Huitao Fan; Yilin Zhao; Rohan Bareja; Rui Lu; Elizabeth M Wilson; Andrea Sboner; Young E Whang; Deyou Zheng; Joel S Parker; H Shelton Earp; Gang Greg Wang Journal: Mol Cell Date: 2018-09-27 Impact factor: 17.970
Authors: Bin He; Rainer B Lanz; Warren Fiskus; Chuandong Geng; Ping Yi; Sean M Hartig; Kimal Rajapakshe; John Shou; Liping Wei; Shrijal S Shah; Christopher Foley; Sue Anne Chew; Vijay K Eedunuri; Diego J Bedoya; Qin Feng; Takashi Minami; Constantine S Mitsiades; Anna Frolov; Nancy L Weigel; Susan G Hilsenbeck; Daniel G Rosen; Timothy Palzkill; Michael M Ittmann; Yongcheng Song; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades Journal: Proc Natl Acad Sci U S A Date: 2014-12-08 Impact factor: 11.205